Pacira BioSciences, Inc. (PCRX) Stock Analysis & Investment Frameworks
Pacira BioSciences, Inc. (PCRX) stock analysis on Invetso. Review Pacira BioSciences, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Pacira BioSciences, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Country: US
Pacira BioSciences, Inc. Key Financial Metrics
- Market Cap: $1.45B
- Revenue: $726.41M
- P/E Ratio: 202.33
- ROE: 2.13%
- ROIC: 1.35%
- Dividend Yield: N/A
About Pacira BioSciences, Inc.
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.